The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients. It combines genomic sequencing with in vitro functional drug testing using patient-derived spheroids/organoids.
Signed informed consent form
≥ 18 years of age
Willing and able to comply with the protocol for the duration of the study, including data and sample collection
Patient scheduled for surgery or biopsy (primary tumour or metastasis) PDAC
Female patient, pregnant, planning a pregnancy or breastfeeding.
Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
Patient unable to understand and provide informed consent and has no family member representing him/her.
Patients with any other life-threatening illness, significant organ dysfunction or any clinically relevant conditions that, according to the hospital physician, could compromise the patient's safety.
Luxembourg Institute of Health
Lead sponsor
Hopitaux Robert Schuman
Collaborator